A long-term study found that about half of participants who took eptinezumab (sold under the brand name Vyepti) had their migraine days reduced by at least 75 percent after 12 weeks. Many maintained that relief for nearly two years.

Thanks! You've successfully submitted your vote.

Sign up to view the results!

Continue with Facebook

Continue with Google

Sign up with your email

By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.

Already a Member? Log in

What Is Eptinezumab?

Eptinezumab is a prescription medicine used to help prevent migraine attacks in adults. It was approved by the U.S. Food and Drug Administration (FDA) in February 2020 for the preventive treatment of both chronic and episodic migraine.

Eptinezumab belongs to a class of drugs called calcitonin gene-related peptide (CGRP) inhibitors. These medicines work by blocking a protein called CGRP, which is believed to play a key role in starting migraine attacks. By stopping CGRP, eptinezumab can help reduce the number of migraine days people experience.

Eptinezumab is given as an intravenous (IV) infusion, meaning it’s delivered through a vein by a healthcare provider. Infusions are typically done once every three months (every 12 weeks).

What the Study Found

The results come from a phase 3 clinical trial that tested the long-term use of eptinezumab in 128 adults with chronic migraine. Participants received infusions every 12 weeks for up to 84 weeks (about 1.5 years). The study looked at how many people saw their headache days reduced by at least half (50 percent) or three-quarters (75 percent) after early treatment — and whether that improvement lasted up to 84 weeks.

Among the 100 people who completed all study visits up to 84 weeks:

• Seventy-eight participants had at least a 50 percent reduction in monthly headache days at 12 weeks.
• Seventy-seven had at least a 50 percent reduction at 24 weeks.
• Sixty-three had at least a 75 percent reduction at 12 weeks.
• Fifty-five had at least a 75 percent reduction at 24 weeks.

Most people who experienced these early improvements kept those benefits through week 84:

• Of the 78 people with at least a 50 percent reduction in headaches at 12 weeks, 78 percent kept it through week 84.
• Of those with at least a 50 percent reduction at 24 weeks, 83 percent kept it through week 84.
• Of those with at least a 75 percent reduction at 12 weeks, 54 percent kept it through week 84.
• Of those with at least a 75 percent reduction at 24 weeks, 69 percent kept it through week 84.

Why This Matters if You’re Living With Chronic Migraine

Many people with chronic migraine try several treatments before finding one that helps. This study suggests that eptinezumab may offer quick relief for some people, and that those who see early improvement may be more likely to keep experiencing fewer migraine days over the long term.

At the same time, the study shows that results can change over time, which is common with some migraine treatments.

This study focused on people who had not found enough relief from other migraine therapies. If you’re still searching for a treatment that works for you, or if your current treatment is no longer meeting your needs, talk with your healthcare provider. Together, you can discuss your options and find a plan that fits your goals.

Learn more about migraine treatments and how they work.

Join the Conversation

On MyMigraineTeam, people share their experiences with migraine, get advice, and find support from others who understand.

Have you had long-term success with migraine treatment? Let others know in the comments below.

Are your headaches a symptom of migraine? Get a quick assessment.